The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology.

Millar JE, Fanning JP, McDonald CI, McAuley DF, Fraser JF. · 2016

Read The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. by Millar JE, Fanning JP, McDonald CI, McAuley DF, Fraser JF. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5125043.txt.

Introduction

Jonathan E. Millar, Jonathon P. Fanning, Charles I. McDonald, Daniel F. McAuley, and John F. Fraser reviewed inflammation during ECMO in Critical Care in 2016. ECMO machines take over heart or lung work for short spells, and their use has spread fast, yet patients still face high rates of harm and death.

One harm is the body's reaction to blood running over the machine's foreign surfaces. That contact wakes the innate immune system widely, in a response much like the body-wide inflammation seen after heart bypass surgery, and unchecked it can injure organs. The review traces how immune arms, blood vessel linings, and clotting interact in this response. Understanding the chain, the authors argue, should guide gentler circuits and better risk calls at the bedside.

Catalog record

CREATORMillar JE, Fanning JP, McDonald CI, McAuley DF, Fraser JF.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE60 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5125043

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology By Jonathan E Millar, Jonathon P Fanning, Charles I McDonald, Daniel F McAuley, John F Fraser Published in: Critical Care DOI: 10.1186/s13054-016-1570-4 ABSTRACT Abstract Extracorporeal membrane oxygenation (ECMO) is a technology capable of providing short-term mechanical support to the heart, lungs or both. Over the last decade, the number of centres offering ECMO has grown rapidly. At the same time, the indications for its use have also been broadened. In part, this trend has been supported by advances in circuit design and in cannulation techniques. Despite the widespread adoption of extracorporeal life support techniques, the use of ECMO remains associated with significant morbidity and mortality. A complication witnessed during ECMO is the inflammatory response to extracorporeal circulation. This reaction shares similarities with the systemic inflammatory response syndrome (SIRS) and has been well-documented in relation to cardiopulmonary bypass. The exposure of a patient’s blood to the non-endothelialised surface of the ECMO circuit results in the widespread activation of the innate immune system; if unchecked this may result in inflammation and organ injury. Here, we review the pathophysiology of the inflammatory response to ECMO, highlighting the complex interactions between arms of the innate immune response, the endothelium and coagulation. An understanding of the processes involved may guide the design of therapies and strategies aimed at ameliorating inflammation during ECMO. Likewise, an appreciation of the potentially deleterious inflammatory effects of ECMO may assist those weighing the risks and benefits of therapy. Keywords: Extracorporeal membrane oxygenation, ECMO, Inflammation, SIRS, Coagulation BACKGROUND Extracorporeal membrane oxygenation (ECMO) is a technology capable of providing short-term mechanical support to the heart, lungs or both. Despite having first been employed clinically in the 1970s [1], the more widespread use of ECMO in critically ill adult patients is a recent phenomenon [2]. Over the last decade, the number of centres offering ECMO has grown rapidly. At the same time, the indications for ECMO in adults have expanded beyond acute severe respiratory and cardiac failure [3] to include extracorporeal cardiopulmonary resuscitation (ECPR) [4] and as a bridge to lung transplantation [5]. Due to its origins, the use of ECMO is much better established in neonatal and paediatric populations [6]. In fact, neonatal ECMO for respiratory failure accounts for 43% of the Extracorporeal Life Support Organisation (ELSO) registry, comprising 25 years of records of paediatric and adult patients undergoing ECMO [7]. Survival rates in neonates and children supported with ECMO, especially in cases of respiratory failure, are generally high [8]. For adults, it is difficult to quantify the mortality of patients undergoing ECMO. Several studies have varied in their reported mortalities based on indication and modality [8, 9], ranging from 76% in one cohort undergoing ECMO and dialysis [10] to 37% in a mixed veno-venous (VV)/veno-arterial (VA) ECMO group [11]. The ELSO registry, between 1989 and 2014, reports mortalities for respiratory and cardiac ECMO, of 57% and 41% respectively [7]. In addition, there are a number of complications that may occur, any of which is capable of inflicting serious morbidity. These can be broadly separated into those related to the ECMO device (e.g., oxygenator or pump malfunction, circuit clotting, cannula issues) and physiological complications (e.g., bleeding, haemolysis, and infection). In this review, we examine the pathophysiology of one less well-recognised complication, the inflammatory response to ECMO. THE INFLAMMATORY RESPONSE TO ECMO The initiation of ECMO is associated with an immediate and complex inflammatory reaction, similar to that seen in systemic inflammatory response syndrome (SIRS) [12]. At that moment when the patient’s blood first comes into contact with the foreign surface of the extracorporeal circuit, a variety of coagulative and inflammatory cascades are activated (Fig. 1). Levels of pro-inflammatory cytokines rise rapidly [13–19], which, in association with activation of the complement and contact systems [20–25], results in leukocyte activation [26–28]. This innate immune response, if severe, persistent or unchecked by a compensatory anti-inflammatory response (CARS) [29], may lead to endothelial injury, disrupted microcirculation, and end-organ dysfunction [30–35]. Despite major improvements in pump and circuit design, oxygenators and the advent of heparin-bonded surfaces, the SIRS response to ECMO remains a clinical concern. While a large volume of work has been directed towards elucidating and targeting the inflammatory response to cardiopulmonary bypass (CPB) [36–38], a closely related form of extracorporeal circulation, much less has been devoted to studying the inflammatory response to ECMO. [Figure: The inflammatory response to extracorporeal membrane oxygenation (ECMO). During ECMO, the complement and contact systems are activated as a result of blood-biomaterial interaction. The alternative complement pathway (AP) is primarily responsible for producing the anaphylatoxins C3a and C5a and the membrane attack complex (MAC). This occurs as the result of increased hydrolysis of C3 on the biomaterial surface. The contact system is responsible for producing activated factor XII (FXIIa), which induces the intrinsic coagulation pathway, leading to thrombin formation. Products produced by each of these systems, promote the production of pro-inflammatory cytokines and have direct effects on leukocytes, platelets and the vascular endothelium. In particular, neutrophils are activated, leading to increased neutrophilic infiltration of tissue and eventual organ damage] DIFFERENCES BETWEEN ECMO AND CPB ECMO and CPB are closely related and share several similarities. Both techniques generate a biomaterial-induced inflammatory response in patients. Despite this, there are important distinctions between ECMO and CPB (Table 1), of which anyone attempting to infer from one to the other must be aware. [Table: Key differences between extracorporeal membrane oxygenation (ECMO) and cardiopulmonary bypass (CPB)] The most obvious distinction between ECMO and CPB is in the duration of support provided. CPB is commonly employed for only minutes to hours to facilitate a surgical procedure. Conversely, ECMO, used in patients with severe organ failure, can be prolonged for weeks to months. This difference in duration requires a different approach to anticoagulation. During CPB, loading doses of unfractionated heparin between 300 and 500 U/kg may be used [39], versus 40–80 U/kg during ECMO [40]. Upon the completion of CPB, protamine sulphate is administered to reverse the effects of heparin, a practice which is avoided during and at the conclusion of ECMO. This is an important distinction, given that the formation of protamine-heparin complexes is known to exacerbate the inflammatory response (via activation of the classical and lectin complement pathways) [41, 42]. Hypothermia is mandatory during CPB, but not commonly employed during ECMO. Likewise, haemodilution, which may also be employed during CPB, is not seen to the same degree during ECMO. Large observational studies have demonstrated an association between the lowest haematocrit recorded during CPB and post-operative mortality [43]. One suggested explanation for this is that haemodilution leads to increased neutrophil activation [44]. As part of the surgical nature of conventional CPB, cardiotomy suctioning, venting of blood and venous reservoirs are incorporated into circuits. This introduces a blood-air interface. Multiple studies have detected higher levels of pro-inflammatory cytokines in cardiotomy-suctioned blood and, in some instances, lower levels of anti-inflammatory cytokines, such as IL-10 [45–47]. The absence of an air/blood interface during ECMO may be a factor in reducing the inflammatory response. Commonly, perfusion during CPB is non-pulsatile [48]. During VA-ECMO, depending on the residual function of the native heart, varying degrees of pulsatile flow are

Read the complete text